Equity Overview
Price & Market Data
Price: $3.62
Daily Change: -$0.12 / 3.31%
Daily Range: $3.60 - $3.86
Market Cap: $1,083,592,856
Daily Volume: 2,646,663
Performance Metrics
1 Week: -0.14%
1 Month: -9.95%
3 Months: -21.48%
6 Months: 20.67%
1 Year: 25.69%
YTD: 22.30%
Company Details
Employees: 596
Sector: Health technology
Industry: Biotechnology
Country:
Details
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.